Search

PTC Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

72.75 3.84

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

67.72

Max

71.37

Schlüsselkennzahlen

By Trading Economics

Einkommen

86M

83M

Verkäufe

88M

361M

KGV

Branchendurchschnitt

7.597

57.371

EPS

0.92

Gewinnspanne

23.16

Angestellte

991

EBITDA

198M

162M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+41.92% upside

Dividenden

By Acuity

Nächstes Ergebnis

3. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-205M

6.1B

Vorheriger Eröffnungskurs

68.91

Vorheriger Schlusskurs

72.75

Nachrichtenstimmung

By Acuity

54%

46%

276 / 340 Ranking in Healthcare

PTC Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Aug. 2026, 19:26 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid a broader market rebound in safe-haven assets.

20. Aug. 2026, 20:02 UTC

PTC Therapeutics shares are lower amid significant downward pressure on biotechnology stocks. The stock remains below its 20-day moving average.

19. Aug. 2026, 19:46 UTC

News

PTC Therapeutics is acquiring the ST-920 gene therapy asset for $111 million, including potential milestone payments, as shares trade higher since Tuesday's close.

18. Aug. 2026, 19:36 UTC

PTC Therapeutics Inc shares are lower amid cautious market sentiment influenced by rising treasury yields and inflation concerns. No specific news was identified for the decline.

14. Aug. 2026, 19:46 UTC

PTC Therapeutics shares are lower, reflecting broader market sentiment after U.S. retail sales unexpectedly declined in July. The stock is below its 20-day moving average.

13. Aug. 2026, 19:36 UTC

News
Social Media

PTC Therapeutics announced the acquisition of ST-920 for $111 million. Shares are lower amid ongoing bearish trends, despite Wells Fargo's Overweight rating and $109 price target.

12. Aug. 2026, 23:51 UTC

Social Media
News

PTC Therapeutics acquires ST-920 gene therapy for $111 million, enhancing its rare disease portfolio. Shares are higher in after-market hours.

11. Aug. 2026, 19:46 UTC

PTC Therapeutics Inc is trading lower amid market adjustments following last Friday's weak jobs report and ahead of upcoming U.S. inflation data releases.

10. Aug. 2026, 19:46 UTC

PTC Therapeutics shares are higher today amid broader market uncertainty regarding the Federal Reserve's interest rate policy following last week's employment report.

7. Aug. 2026, 21:02 UTC

PTC Therapeutics Inc shares are lower in after-market hours, reversing a trend of higher finishes over the past five sessions. No specific news was identified.

6. Aug. 2026, 19:56 UTC

PTC Therapeutics Inc. is higher today, having reached a peak earlier in the session. No specific news was identified to explain the price action.

5. Aug. 2026, 19:26 UTC

News

PTC Therapeutics Inc. will participate in upcoming investor conferences. Shares are lower today, remaining near the lower end of their one-month range.

4. Aug. 2026, 20:07 UTC

PTC Therapeutics shares are higher today, buoyed by positive market sentiment amid a significant decline in crude oil prices.

3. Aug. 2026, 19:46 UTC

News

PTC Therapeutics reported second-quarter revenue of $360.52 million and raised its full-year outlook to $1.18 billion to $1.28 billion, with shares advancing today.

31. Juli 2026, 21:01 UTC

PTC Therapeutics Inc shares rose in after-market trading, despite broader market concerns over inflation and interest rates amid rising crude oil prices.

30. Juli 2026, 22:31 UTC

News

PTC Therapeutics raised its 2026 revenue guidance after reporting strong Q2 results, with EPS of $0.92 exceeding estimates. Shares are higher in after-market trading.

29. Juli 2026, 18:26 UTC

PTC Therapeutics Inc shares are lower today, reflecting a broader decline. Market participants await the Federal Reserve's interest rate decision this afternoon.

28. Juli 2026, 18:31 UTC

News

PTC Therapeutics shares are lower as analysts anticipate a 5.6% revenue decline in Q2, contrasting with last year's growth of 24.2%.

27. Juli 2026, 20:06 UTC

PTC Therapeutics Inc shares are lower today amid broader market declines, influenced by falling oil prices and Treasury yields ahead of the Federal Reserve meeting.

22. Juli 2026, 17:16 UTC

PTC Therapeutics shares are lower today, trading near the lower end of their one-month range amid rising crude oil prices affecting the broader market.

21. Juli 2026, 18:01 UTC

PTC Therapeutics shares are higher today, reflecting positive market sentiment. The stock remains near the lower end of its one-month range.

20. Juli 2026, 19:56 UTC

News

PTC Therapeutics shares are lower as Wells Fargo cuts price target to $93.00 from $95.00 while keeping an Overweight rating.

Peer-Vergleich

Kursveränderung

PTC Therapeutics Inc Prognose

Kursziel

By TipRanks

41.92% Vorteil

12-Monats-Prognose

Durchschnitt 99.09 USD  41.92%

Hoch 130 USD

Tief 70 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für PTC Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

9

Buy

1

Halten

1

Sell

Stimmung

By Acuity

276 / 340 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
help-icon Live chat